Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer
In the past few years, impressing improvements have been made in the treatment of advanced colorectal cancer. Following decades of modest achievements, in which it was just a matter of dose and schedule for 5-FU and leucovorin—the only treatment then available—first, the development of irinotecan an...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2011-12-01
|
| Series: | Oncology Reviews |
| Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/72 |
| id |
doaj-03bfb2a6ed444341b089cc7df045abc5 |
|---|---|
| record_format |
Article |
| spelling |
doaj-03bfb2a6ed444341b089cc7df045abc52020-11-25T03:32:27ZengPAGEPress PublicationsOncology Reviews1970-55571970-55652011-12-013110.4081/oncol.2009.166Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancerCamillo Porta0Medical Oncology and Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, IRCCS San Matteo University Hospital Foundation, PaviaIn the past few years, impressing improvements have been made in the treatment of advanced colorectal cancer. Following decades of modest achievements, in which it was just a matter of dose and schedule for 5-FU and leucovorin—the only treatment then available—first, the development of irinotecan and oxaliplatin, and then the use of the two biologicals, bevacizumab and cetuximab, have dramatically improved the life expectancy of our colorectal cancer patients...http://www.oncologyreviews.org/index.php/or/article/view/72 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Camillo Porta |
| spellingShingle |
Camillo Porta Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer Oncology Reviews |
| author_facet |
Camillo Porta |
| author_sort |
Camillo Porta |
| title |
Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer |
| title_short |
Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer |
| title_full |
Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer |
| title_fullStr |
Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer |
| title_full_unstemmed |
Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer |
| title_sort |
is more better than less? caveats from bevacizumab and cetuximab combination in colorectal cancer |
| publisher |
PAGEPress Publications |
| series |
Oncology Reviews |
| issn |
1970-5557 1970-5565 |
| publishDate |
2011-12-01 |
| description |
In the past few years, impressing improvements have been made in the treatment of advanced colorectal cancer. Following decades of modest achievements, in which it was just a matter of dose and schedule for 5-FU and leucovorin—the only treatment then available—first, the development of irinotecan and oxaliplatin, and then the use of the two biologicals, bevacizumab and cetuximab, have dramatically improved the life expectancy of our colorectal cancer patients... |
| url |
http://www.oncologyreviews.org/index.php/or/article/view/72 |
| work_keys_str_mv |
AT camilloporta ismorebetterthanlesscaveatsfrombevacizumabandcetuximabcombinationincolorectalcancer |
| _version_ |
1724568158196465664 |